These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35595169)

  • 41. An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase.
    Pucheta-Martínez E; Saladino G; Morando MA; Martinez-Torrecuadrada J; Lelli M; Sutto L; D'Amelio N; Gervasio FL
    Sci Rep; 2016 Apr; 6():24235. PubMed ID: 27063862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Revealing the favorable dissociation pathway of type II kinase inhibitors via enhanced sampling simulations and two-end-state calculations.
    Sun H; Tian S; Zhou S; Li Y; Li D; Xu L; Shen M; Pan P; Hou T
    Sci Rep; 2015 Feb; 5():8457. PubMed ID: 25678308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.
    Fronik P; Gaiser BI; Sejer Pedersen D
    J Med Chem; 2017 May; 60(10):4126-4134. PubMed ID: 28140580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Motions of Allosteric and Orthosteric Ligand-Binding Sites in Proteins are Highly Correlated.
    Ma X; Meng H; Lai L
    J Chem Inf Model; 2016 Sep; 56(9):1725-33. PubMed ID: 27580047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.
    Rettenmaier TJ; Fan H; Karpiak J; Doak A; Sali A; Shoichet BK; Wells JA
    J Med Chem; 2015 Oct; 58(20):8285-8291. PubMed ID: 26443011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.
    Brear P; Ball D; Stott K; D'Arcy S; Hyvönen M
    J Med Chem; 2020 Nov; 63(21):12786-12798. PubMed ID: 33119282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Productive induced metastability in allosteric modulation of kinase function.
    Montes de Oca J; Rodriguez Fris A; Appignanesi G; Fernández A
    FEBS J; 2014 Jul; 281(13):3079-91. PubMed ID: 24823615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Insights on the Conformational Transitions and Activity Regulation of the c-Met Kinase Induced by Ligand Binding.
    Liu Z; Liang K; Liu W; Jiang T; Zhou R; Duan M; Zheng Z
    J Chem Inf Model; 2023 Jul; 63(13):4147-4157. PubMed ID: 37357790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In Silico Reoptimization of Binding Affinity and Drug-Resistance Circumvention Ability in Kinase Inhibitors: A Case Study with RL-45 and Src Kinase.
    Koneru JK; Sinha S; Mondal J
    J Phys Chem B; 2019 Aug; 123(31):6664-6672. PubMed ID: 31310546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perturbation Approaches for Exploring Protein Binding Site Flexibility to Predict Transient Binding Pockets.
    Kokh DB; Czodrowski P; Rippmann F; Wade RC
    J Chem Theory Comput; 2016 Aug; 12(8):4100-13. PubMed ID: 27399277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases.
    Verma J; Vashisth H
    Proteins; 2024 Aug; 92(8):905-922. PubMed ID: 38506327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cooperativity between the orthosteric and allosteric ligand binding sites of RORγt.
    de Vries RMJM; Meijer FA; Doveston RG; Leijten-van de Gevel IA; Brunsveld L
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
    Ma Y; Qi B; Ning M; Zhang L; An Z; Zhao J
    Eur Biophys J; 2022 Apr; 51(3):283-295. PubMed ID: 35307752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation.
    Kist R; Caceres RA
    J Biomol Struct Dyn; 2017 Dec; 35(16):3555-3568. PubMed ID: 27860549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors.
    Lombard CK; Davis AL; Inukai T; Maly DJ
    Biochemistry; 2018 Oct; 57(40):5897-5909. PubMed ID: 30211540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cross-talk between allosteric and orthosteric binding sites of γ-amino butyric acid type A receptors (GABA
    Payghan PV; Nath Roy S; Bhattacharyya D; Ghoshal N
    J Biomol Struct Dyn; 2019 Aug; 37(12):3065-3080. PubMed ID: 30608219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational allosteric ligand binding site identification on Ras proteins.
    McCarthy M; Prakash P; Gorfe AA
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):3-10. PubMed ID: 26487442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases.
    Chakraborty S; Inukai T; Fang L; Golkowski M; Maly DJ
    ACS Chem Biol; 2019 Jun; 14(6):1249-1259. PubMed ID: 31038916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.
    Lamba V; Ghosh I
    Curr Pharm Des; 2012; 18(20):2936-45. PubMed ID: 22571662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.